サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：脳性麻痺治療の世界市場-2023-2030
市場調査レポート
商品コード
1272770

脳性麻痺治療の世界市場-2023-2030

Global Cerebral Palsy Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
脳性麻痺治療の世界市場-2023-2030
出版日: 2023年05月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

脳性麻痺治療の世界市場は、2022年に32億740万米ドルに達し、2030年には42億8,050万米ドルに達することで有利な成長が予測されます。世界の脳性麻痺治療市場は、予測期間中（2023-2030年）に3.7%のCAGRを示すと予測されています。主要企業は、脳性麻痺治療市場で強力な競争相手として目立つために、パートナーシップ、合併、買収、地域拡大などの戦略を採っています。新製品の発売や研究開発への注力の強化は、主要企業が市場での存在感を高めるための他の方法の一部です。

例えば、2021年8月31日、体重12kg未満の小児および青少年における神経学的または神経発達障害に起因する慢性唾液漏出症の症状緩和のためのXEOMINの使用が、メルツグループの一部門で神経毒の分野のパイオニアであるメルツセラピューティクスにEUレベルで承認されています。

脳性麻痺（CP）は、体の硬さと運動障害を特徴とする非進行性の慢性疾患の集合体です。胎内で脳が正常に発達しなかったり、出生後の傷害により発症します。四肢の運動機能に影響を及ぼし、バランス障害、筋収縮、協調運動障害、その他の神経症状が生じます。

最も一般的な脳性麻痺は、痙性、失調性運動障害、混合型です。治療法としては、薬物療法、治療法、外科的処置、その他日常機能を改善するための治療法があります。脳性まひの治療法はありません。

さらに、脳性まひ疾患の有病率の増加、迅速な臨床試験、政府からの資金提供や企業の投資の増加は、予測期間中の市場成長を促進すると予想される主要因です。

市場力学

早産の有病率の増加が世界の脳性麻痺治療市場の成長を後押ししている

早産、低出生体重児、多胎児、妊娠中の感染症などは、脳性まひの症例増加につながります。年間推定1,500万人の赤ちゃんが早産で生まれており、10人に1人以上がこのカテゴリーに属しています。毎年、100万人以上の子どもたちが早産による合併症で亡くなっています。生存者の多くは、学習障害や視覚・聴覚障害など、生涯に渡って障害に直面する可能性があります。

また、甲状腺の病気や発作、知的障害など、母親の健康問題が子供の脳性まひを誘発することもあります。さらに、脳性麻痺治療市場の急成長は、脳性まひの発症率の増加、脳性まひの合併症に対する保護者の意識の向上、市場におけるさまざまな治療オプションの利用が可能であることに起因していると考えられます。

例えば、米国疾病管理予防センターによると、米国では1000人中1.5～4人の子供が脳性まひに罹患しているとされています。この症状は、運動、姿勢、バランスを司る脳領域の異常な発達や損傷によって引き起こされます。脳性麻痺は出生前に最も多く発症しますが、出生時や出生直後に困難が生じることもあります。したがって、上記の要因から、脳性まひの治療市場は予測期間中に牽引すると予想されます。

薬別急性副作用が脳性麻痺治療市場の成長を阻害している

薬物療法は脳性麻痺治療の重要な要素であり、症状の管理と生活の質の向上に役立ちますが、副作用を伴うこともあります。例えば、筋弛緩剤は眠気や疲労を引き起こす可能性があり、患者の日常生活動作に影響を与え、学校や仕事に支障をきたす可能性があります。

また、鎮痙剤は脳性麻痺の治療に使用すると、便秘、下痢、腹部膨満感などの胃腸障害を引き起こす可能性があります。したがって、上記の要因のために、脳性麻痺治療市場は予測期間中に阻害されると予想されます。

COVID-19の影響分析

COVID-19は、脳性麻痺治療市場に大きな影響を及ぼしています。ヘルスケア施設はCOVID-19患者を優先し、緊急性のない治療の遅延やキャンセルにつながりました。パンデミックはヘルスケアサービスへのアクセスを低下させ、脳性まひ患者が必要な治療を受けることをより困難にしています。

さらに、パンデミックによって医薬品や医療機器のサプライチェーンが寸断され、医療従事者が脳性まひの患者さんを治療することがより困難になっています。同様に、臨床試験の遅延など、脳性まひの治療に用いられる医薬品の開発、生産、流通にも影響を及ぼしました。

一方、直接ヘルスケア施設を訪れることが困難なため、遠隔医療サービスの普及が進んでいるが、脳性まひの患者さんにとって、必ずしも対面診療の代わりにはなっていないのが現状です。

ロシア・ウクライナ紛争の分析

ロシアのウクライナ侵攻は人道的危機を引き起こし、知的障がい者とその家族に不釣り合いな影響を及ぼしています。孤児院にいる障がいを持つ子どもたちは、活動不足や痙性脳性麻痺の治療で体がねじれ、窮屈になっていたため、慈善団体が痛みを軽減する治療を定期的に行っていました。同様に、ウクライナのglobal fund for Childrenのパートナーは、障害を持つ子どもたちとその家族がより安全な地域に避難し、必要な物資を手に入れるのを支援しています。したがって、紛争は世界の脳性麻痺治療市場に中程度の影響を及ぼしています。

人工知能の影響分析

AIシステムは、脳性まひの子どもたちの予後を精緻化し、管理選択を支援します。例えば、スタンフォード大学とミネソタ州のジレット小児専門病院の研究者は、人工知能と1台のカメラで撮影した映像を使って、脳性まひの診断を受けた人の運動障害を分析しました。このシステムは安価で使いやすく、オープンソースであるため、医師は神経疾患や筋骨格系疾患の特定、進行状況の測定、治療をより適切に行えるようになります。

目次

第1章 調査手法と範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

  • 薬物タイプ別スニペット
  • 疾患別スニペット
  • 販売チャネル別スニペット
  • 地域別スニペット

第4章 市場力学

  • 影響要因
    • 促進要因
      • 早産患者の増加により、予測期間中の脳性麻痺治療市場の成長が促進
    • 抑制要因
      • 薬剤別急性副作用が、予測期間中の脳性麻痺治療市場の成長を阻害
    • 機会
      • 共同研究の増加
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • アンメットニーズ
  • 法規制分析

第6章 COVID-19の分析

  • COVID-19の分析
    • COVID-19導入前シナリオ
    • 現在のCOVID-19シナリオ
    • COVID-19後または将来のシナリオ
  • COVID-19の中での価格・ダイナミクス
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカー各社の戦略的取り組み
  • おわりに

第7章 ロシア・ウクライナ紛争分析

第8章 人工知能の影響分析

第9章 薬物タイプ別

  • 抗けいれん薬
  • 抗コリン薬
  • 抗うつ剤
  • その他

第10章 疾患タイプ別

  • 痙性脳性麻痺
  • 混合型脳性麻痺
  • 運動障害性脳性麻痺
  • 運動失調性脳性麻痺

第11章 流通チャネル別

  • 病院内薬局
  • 小売店・調剤薬局
  • オンライン薬局

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第13章 競合情勢

  • 競合シナリオ
  • 製品ベンチマーク
  • 企業シェア分析
  • 主な発展と戦略

第14章 企業プロファイル

  • Merz Pharmaceuticals, LLC.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展状況
  • Pfizer Inc.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc.
  • Novartis
  • AbbVie Inc.
  • Par Pharmaceutical
  • Hikma Pharmaceuticals Plc.

第15章 付録

目次
Product Code: PH4902

Market Overview

The global cerebral palsy treatment market reached US$ 3,207.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 4,280.5 million by 2030. The global cerebral palsy treatment market is expected to exhibit a CAGR of 3.7% during the forecast period (2023-2030). The key players are adopting strategies such as partnerships, mergers, acquisitions, and regional expansion to stand out as strong competitors in the cerebral palsy treatment market. Novel product launches and enhanced focus on research and development are some of the other ways where the leading players can improve their market presence.

For instance, on August 31, 2021, the use of XEOMIN for the relief of symptoms of chronic sialorrhea caused by neurological or neurodevelopmental disorders in children and adolescents weighing less than 12 kg has been approved on an EU level for Merz Therapeutics, a division of the Merz Group and a pioneer in the field of neurotoxins.

Cerebral Palsy (CP) is a collection of non-progressive, chronic illnesses marked by stiffness and mobility disability. It arises when the brain does not develop normally in the womb or due to a post-natal injury. It can affect motor function in all four limbs, resulting in balance issues, muscular contracture, coordination issues, and other neurological symptoms.

The most common cerebral palsy is spastic, ataxic dyskinetic, and mixed. Treatment options include medications, therapies, surgical procedures, and other treatments to improve daily functioning. There is no cure for cerebral palsy.

Furthermore, the increasing prevalence of cerebral palsy disorder, rapid clinical trials, and increasing government funding and company investments are key factors expected to drive the market growth over the forecast period.

Market Dynamics

The increasing prevalence of premature births is boosting the global cerebral palsy treatment market growth

Premature birth, low birth weight, multiple childbirths, and infectious diseases during pregnancy can lead to a rise in cerebral palsy cases. An estimated 15 million babies are born prematurely yearly, with more than one out of every ten falling under this category. Every year, over one million children die due to premature birth complications. Many survivors may face obstacles for the rest of their life, such as learning disabilities and visual and hearing problems.

Moreover, health problems in the mother, such as thyroid illness, seizures, intellectual impairment, and so on, might induce cerebral palsy in the kid. In addition, the rapid growth of the cerebral palsy treatment market can be attributed to an increase in the incidence of cerebral palsy and an increase in parental awareness of cerebral palsy complications, and the availability of various treatment options in the market.

For instance, according to the Centres for Disease Control and Prevention, 1.5 to 4 children out of every 1000 in the United States have cerebral palsy. The condition is caused by aberrant development or injury to brain regions that govern movement, posture, and balance. Cerebral palsy is most frequent before birth, but difficulties can arise during or immediately after birth. Thus, from the above factors, the cerebral palsy treatment market is expected to drive over the forecast period.

Acute side effects due to medications are hampering the growth of the global cerebral palsy treatment market

Medications are an important part of cerebral palsy treatment, helping to manage symptoms and improve quality of life, but can also have side effects. For instance, muscle relaxants can cause drowsiness and fatigue, which can affect a patient's ability to perform daily activities and interfere with their school or work.

Similarly, antispasmodics can cause gastrointestinal disturbances when used to treat cerebral palsy, such as constipation, diarrhea, and bloating. Hence, owing to the above factors, the cerebral palsy treatment market is expected to be hampered over the forecast period.

COVID-19 Impact Analysis

COVID-19 has had a significant impact on the cerebral palsy treatment market. Healthcare facilities have prioritized COVID-19 patients, leading to delays or cancellations of non-emergency treatments. The pandemic has caused reduced access to healthcare services, making it more difficult for patients with cerebral palsy to access the care they need.

Moreover, the pandemic has disrupted supply chains for medications and medical equipment, making it more difficult for healthcare providers to treat patients with cerebral palsy. Likewise, it had a sign on the development, production, and distribution of drugs used to treat cerebral palsy, including delayed clinical trials.

In contrast, telemedicine services have become increasingly popular due to the difficulty of visiting healthcare facilities in person, but it is not always a substitute for in-person care for patients with cerebral palsy.

Russia-Ukraine Conflict Analysis

Russia's invasion of Ukraine has caused a humanitarian crisis, disproportionately impacting people with intellectual disabilities and their families. Children in orphanages with disabilities had become twisted and constricted due to lack of activity and treatment for spastic cerebral palsy, so charitable organizations provided regular treatments to reduce pain. Similarly, global fund for Children partners in Ukraine is helping children with disabilities and their families evacuate to safer areas and get essential supplies. Therefore, the conflict has had a moderate impact on the global cerebral palsy treatment market.

Artificial Intelligence Impact Analysis

AI systems help to refine prognosis and assist in management selection for children with cerebral palsy. For instance, researchers at Stanford and Gillette Children's Specialty Hospital in Minnesota have used artificial intelligence and video shot with a single camera to analyze movement impairment in people diagnosed with cerebral palsy. This system is inexpensive, easy to use, and open-source, allowing doctors to better identify, measure progress, and treat neurological and musculoskeletal disorders.

Segment Analysis

The global cerebral palsy treatment market is segmented based on drug type, disease type, distribution channel, and region.

The spastic cerebral palsy segment is expected to hold a dominant position in the market over the forecast period

The spastic cerebral palsy segment accounted for the highest market stake accounting for approximately 70.4% of the cerebral palsy treatment market in 2022. Spastic cerebral palsy is a developmental disorder caused by brain damage before birth, during delivery, or in the first few years of life. Children are the most affected and develop co-occurring symptoms, driving revenue growth in this segment.

Spastic CP, such as quadriplegia, hemiplegia, and diplegia, affects the body the most. Treatment options such as physical therapy, medication, baclofen pump, spine or cord surgery, muscle release, and tendon lengthening surgery are used to prevent symptoms, creating demand for this segment.

Moreover, companies such as Merz Pharmaceuticals, Teva Pharmaceuticals, Supernus Pharmaceuticals, and Rohto Pharmaceutical are conducting clinical trials to explore new treatment options, driving revenue growth.

Geographical Analysis

The increasing prevalence of cerebral palsy disorder, and increasing funding by government organizations to dominate the North America region

North America is expected to dominate the worldwide cerebral palsy treatment market, accounting for around 2/5th of this market, with the U.S. being the major contributor. For instance, the U.S. government offers a variety of financial benefits to people with cerebral palsy, such as benefit programs, scholarships, grants, and subsidized loans. The most common resources are Supplemental Security Income (SSI), the Individuals With Disabilities Education Act (IDEA), and Medicaid.

Competitive Landscape

The major global players in the market include Merz Pharmaceuticals, LLC., Pfizer Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Novartis, AbbVie Inc., Par Pharmaceutical, and Hikma Pharmaceuticals Plc among others.

Why Purchase the Report?

  • To visualize the global cerebral palsy treatment market segmentation based on the drug type, disease type, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of cerebral palsy treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global cerebral palsy treatment market report would provide approximately 61 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Type
  • 3.2. Snippet by Disease Type
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of premature births is boosting the global cerebral palsy treatment market growth during the forecast period.
    • 4.1.2. Restraints
      • 4.1.2.1. Acute side effects due to medications are hampering the growth of the global cerebral palsy treatment market in the forecast period.
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing collaborative research efforts
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine Conflict Analysis

8. Artificial Intelligence Impact Analysis

9. By Drug Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 9.1.2. Market Attractiveness Index, By Drug Type
  • 9.2. Anticonvulsants*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Anticholinergics
  • 9.4. Antidepressants
  • 9.5. Other

10. By Disease Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.1.2. Market Attractiveness Index, By Disease Type
  • 10.2. Spastic Cerebral Palsy*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Mixed Cerebral Palsy
  • 10.4. Dyskinetic Cerebral Palsy
  • 10.5. Ataxic Cerebral Palsy

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Retail stores and Pharmacies
  • 11.4. Online Pharmacies

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.6.1. The U.S.
      • 12.2.6.2. Canada
      • 12.2.6.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.6.1. Germany
      • 12.3.6.2. The U.K.
      • 12.3.6.3. France
      • 12.3.6.4. Italy
      • 12.3.6.5. Spain
      • 12.3.6.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.6.1. Brazil
      • 12.4.6.2. Argentina
      • 12.4.6.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.6.1. China
      • 12.5.6.2. India
      • 12.5.6.3. Japan
      • 12.5.6.4. Australia
      • 12.5.6.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Product Benchmarking
  • 13.3. Company Share Analysis
  • 13.4. Key Developments and Strategies

14. Company Profiles

  • 14.1. Merz Pharmaceuticals, LLC. *
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Pfizer Inc.
  • 14.3. Viatris Inc.
  • 14.4. Teva Pharmaceutical Industries Ltd.
  • 14.5. F. Hoffmann-La Roche Ltd
  • 14.6. GlaxoSmithKline plc.
  • 14.7. Novartis
  • 14.8. AbbVie Inc.
  • 14.9. Par Pharmaceutical
  • 14.10. Hikma Pharmaceuticals Plc.

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us